AMAsena Ayar Madenli

Asena Ayar Madenli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Asena Ayar Madenli has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Urogenital Symptoms are Associated With Bone Mineral Density but not With Metabolic Syndrome in Postmenopausal Women: A Prospective Cross-Sectional Study

    by Asena Ayar Madenli, Serap Cetiner

    Background: Menopause imposes a significant physical and emotional burden on women, affecting their quality of life and overall health. Beyond these challenges, the decline in estrogen levels during menopause is closely associated with adverse changes in bone health and an increased risk of developing metabolic syndrome (MetS), both of which contribute to long-term morbidity. The primary hypothesis of the current study was that the co-existence of low bone mineral density (BMD) and MetS would exacerbate the severity of menopausal symptoms. As the most bothersome menopausal symptoms typically emerge one year before the final menstrual period and gradually subside thereafter, we investigated BMD, MetS, and menopause-related symptoms in postmenopausal women within 10 years of menopause onset. Methods: A total of 193 postmenopausal women were included in this cross-sectional study, which was conducted at a university hospital in Istanbul. At baseline, participants were categorized into MetS and non-MetS groups based on the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria. For comparative analyses, participants were stratified according to MetS status and BMD. Women with osteopenia or osteoporosis based on BMD measurements were combined into the low BMD group. Menopausal symptoms were assessed using the Menopause Rating Scale (MRS). Results: Women with MetS were significantly older and had a longer duration of menopause than those without MetS. All MRS scores were comparable between the MetS and non-MetS groups. Women with low BMD were older, had a longer duration of menopause, and a lower body mass index (BMI) compared to those with normal BMD. The MRS urogenital symptom subscale score was significantly higher among women with low BMD (p = 0.019). Severe urogenital symptoms were observed among women with co-existence of MetS and low BMD. Correlation analyses between MRS scores and other variables yielded negligible negative correlations with age. Conclusions: Low BMD was associated with higher scores on the urogenital subscale of the MRS, whereas MetS showed no significant relationship with menopausal symptoms. Women with both low BMD and MetS experienced more severe urogenital symptoms.


  • Open Access

    Evaluating the efficacy of potential ovarian reserve markers from theca and granulosa cells: INSL3 & TNFR2

    by Asena Ayar Madenli, Inci Oz

    Accurate assessment of ovarian reserve remains challenging in clinical practice, particularly when conventional markers like anti-müllerian hormone (AMH) and antral follicle count show inconsistent results. Despite widespread use, AMH has limitations in predicting reproductive lifespan and oocyte quality. This study evaluated 2 emerging biomarkers, insulin-like peptide-3 (INSL3) and tumor necrosis factor receptor 2 (TNFR2), for ovarian reserve assessment. We included 179 women aged 20 to 40 years. Participants underwent ultrasound evaluation for antral follicle count and blood sampling for hormone measurements. Women were classified using decreased ovarian reserve (DOR) and premature ovarian insufficiency (POI) criteria. INSL3 showed moderate effectiveness in detecting both DOR (area under the curve [AUC]: 0.685) and POI (AUC: 0.711), though not as strong as AMH. TNFR2 was statistically significant in predicting DOR (AUC: 0.651) but ineffective for POI identification. While AMH remained the strongest marker, INSL3 may serve as a supportive indicator for evaluating ovarian reserve, especially in identifying women at risk of POI. TNFR2, despite its biological relevance, shows limited clinical usefulness. These findings indicate INSL3’s potential as a complementary marker to improve individualized assessment of ovarian function.


  • Open Access

    The relationship between polycystic ovary syndrome phenotypes and systemic immune inflammation indices

    by Tuğba Gürbüz, Asena Ayar Madenli, Serap Çetiner

    Aims: Polycystic ovary syndrome (PCOS) displays chronic, low-grade inflammation characterized by an enhanced release of pro-inflammatory cytokines. However, the extent of systemic inflammation and its variations across different PCOS phenotypes has not been sufficiently characterized. The study aimed to investigate the relationship between the presence and phenotypes of PCOS and systemic immune inflammation (SII) and response (SIRI) indices. Methods: A total of 310 newly diagnosed PCOS patients and 105 healthy premenopausal women were included in this retrospective study. PCOS were categorized into four distinct phenotypes: phenotype A [hyperandrogenism (HA), oligomenorrhea (OA), and polycystic ovaries (PCO)], phenotype B (HA and OA), phenotype C (HA and PCO), and phenotype D (OA and PCO). Results: Median SII and SIRI were higher in patients with PCOS than control group. The androgenic phenotypes group, specifically Phenotype A, exhibited elevated levels of SII and SIRI compared to the non-androgenic phenotype group. There was a positive correlation between these indices and hormonal parameters and insulin resistance. These relationships were particularly pronounced in the phenotype A group. Increased SIRI was an independent predictor of PCOS fold (OR = 1.08, p < 0.001). In distinguishing the androgenic phenotypes from the non-androgenic phenotypes, the threshold value of the SIRI was found to be >1.1 with 67.1% sensitivity and 81.2% specificity. It was incapable of distinguishing phenotype B from Phenotype C, but it was found successful in predicting phenotype A among all phenotypes. Conclusion: Elevated SII and SIRI levels were associated with the presence of PCOS and its phenotypes, particularly phenotype A. SIRI demonstrated potential as a screening tool for phenotypic discrimination of PCOS, beyond predicting its presence.


  • Artificial intelligence in reproductive endocrinology: an in-depth longitudinal analysis of ChatGPTv4’s month-by-month interpretation and adherence to clinical guidelines for diminished ovarian reserve

    by Tugba Gurbuz, Oya Gokmen, Belgin Devranoglu, Arzu Yurci, Asena Ayar Madenli

    Objective To quantitatively assess the performance of ChatGPTv4, an Artificial Intelligence Language Model, in adhering to clinical guidelines for Diminished Ovarian Reserve (DOR) over two months, evaluating the model’s consistency in providing guideline-based responses. Design A longitudinal study design was employed to evaluate ChatGPTv4’s response accuracy and completeness using a structured questionnaire at baseline and at a two-month follow-up. Setting ChatGPTv4 was tasked with interpreting DOR questionnaires based on standardized clinical guidelines. Participants The study did not involve human participants; the questionnaire was exclusively administered to the ChatGPT model to generate responses about DOR. Methods A guideline-based questionnaire with 176 open-ended, 166 multiple-choice, and 153 true/false questions were deployed to rigorously assess ChatGPTv4’s ability to provide accurate medical advice aligned with current DOR clinical guidelines. AI-generated responses were rated on a 6-point Likert scale for accuracy and a 3-point scale for completeness. The two-phase design assessed the stability and consistency of AI-generated answers over two months. Results ChatGPTv4 achieved near-perfect scores across all question types, with true/false questions consistently answered with 100% accuracy. In multiple-choice queries, accuracy improved from 98.2 to 100% at the two-month follow-up. Open-ended question responses exhibited significant positive enhancements, with accuracy scores increasing from an average of 5.38 ± 0.71 to 5.74 ± 0.51 (max: 6.0) and completeness scores from 2.57 ± 0.52 to 2.85 ± 0.36 (max: 3.0). It underscored the improvements as significant (p < 0.001), with positive correlations between initial and follow-up accuracy (r = 0.597) and completeness (r = 0.381) scores. Limitations The study was limited by the reliance on a controlled, albeit simulated, setting that may not perfectly mirror real-world clinical interactions. Conclusion ChatGPTv4 demonstrated exceptional and improving accuracy and completeness in handling DOR-related guideline queries over the studied period. These findings highlight ChatGPTv4’s potential as a reliable, adaptable AI tool in reproductive endocrinology, capable of augmenting clinical decision-making and guideline development.


  • Open Access

    Comparison of clinical and biochemical parameters in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome

    by Asena Ayar Madenli, Gönül Özer

    Aims: We aimed to compare the clinical and the biochemical features of the ovulatory versus anovulatory phenotypes of polycystic ovary syndrome (PCOS). Methods: This is a retrospective controlled trial conducted among the women who applied to the İstanbul Liv Vadi Hospital between 2021 and 2023 August and diagnosed as PCOS. PCOS patients (n=290) were diagnosed according to the Rotterdam 2003consensus criteria. Women’s clinical and biochemical parameters such as age, height, weight, body mass index (BMI), waist, hip, waist/hip ratio (WHR), fasting blood sugar (FBS), insulin, homeostatic model-assessment-insulin resistance (HOMA-IR), antimullerian hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) total cholesterol,triglyceride, dehydroepiandrosterone (DHEAS), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) of participants were compared between ovulatory and anovulatory phenotypes. Results: The findings of the study did not demonstrate a statistically significant correlation between ovulatory and anovulatory phenotypes in relation to various factors, including height, weight, BMI, waist circumference, hip circumference, WHR, insulin levels, HOMA-IR, AMH, FSH, E2, TSH, total cholesterol, testosterone, free testosterone, DHEAS, LDL and cholesterol (p-value>0.05). A statistically significant difference was observed between the groups in terms of age, FBS, BMI, LH, and HDL levels. Conclusion: In conclusion, there is no significant difference in PCOS’s ovulatory and anovulatory phenotypes in essential parameters such as insulin resistance and BMI.


  • Open Access

    The role of gestational weight gain rate in the development of maternal iron deficiency anaemia

    by Serap Çetiner, Asena Ayar Madenli, Özlem Kaplan

    Aims: Our aim is to analyze the effect of weight gain rates on the development of anaemia in a homogeneous group of pregnant women taking similar nutritional supplements in our own society and to emphasize the importance of weight control based on this hypothesis. Methods: The study was conducted retrospectively with 127 pregnant women between 20 and 40 years old. Pregnant women in normal weight and having body mass index (BMI) between 18.5 and 24.9 were included in the study. These women were divided into two groups according to the amount of weight they gained during pregnancy: those who weighed less than 11 kg and those who gained 11 kg or more. Ages of patients, number of pregnancies and births, 1st and 3rd trimester weights, 1st and 3rd trimester weight differences, 1st and 3rd trimester hemoglobin (Hgb), hematocrit (Hct), mean corpuscular volume (MCV) measurements were recorded. The correlation of changes between weight gain and blood parameters was evaluated. Results: No statistically significant change was observed between the 1st and 3rd trimester Hgb and Hct averages of pregnant women who gained less than 11 kg during pregnancy. 3rd Trimester Hgb, Hct averages of the pregnant group who gained 11 kg or more were found to be statistically significantly lower than the outset Hgb, Hct averages (p=0.001, p=0.001). No statistically significant difference was observed between the 1st Trimester and 3rd Trimester MCV averages of the 11 kg difference groups (p=0.271, p=0.183). No statistically significant difference was observed between the 1st trimester ferritin averages of the 11 kg difference groups (p = 0.055). 3rd trimester ferritin averages of the >11 kg difference group were found to be statistically significantly lower than the <11 kg difference group (p =0.016). Conclusion: As a result of our study, we can say that rapid weight gain during pregnancy deepens anaemia. Randomized studies continue to be the best source of evidence in testing hypotheses mentioning that early use of iron supplements and strengthening weight control may reduce the risk of IDA.

  • Open Access

    The association between fibrocystic breast and thyroid autoimmunity

    by Serap Çetiner, Asena Ayar Madenli, Halime Çalı Öztürk

    Aims: The relationship between thyroid disorders and breast diseases including breast cancer and benign breast disease, has been a topic of interest and controversy. Our study aimed to investigate the potential association between autoimmune thyroid disease (ATD) and fibrocystic breast disease (FBD) Methods: This retrospective study investigated the relationship between atd an FBD. A total of 242 female patients aged 18 years or older were recruited for the study. Data were collected from medical records and patient interviews. The related parameters were recorded for each participant. Results: This study included two hundred forty-two age-matched (29.78±4.55) and body mass index (BMI)-matched (24±2.38) women. A Mann-Whitney test did not find a statistically significant association between the case and control in terms of Free thyroxine (FT4) (p-value>0.05). There was a statistically significant difference between groups in terms of thyroid-stimulating hormone (TSH) (p-value<0.001), antithyroid peroxidase (Anti-TPO) (p-value<0.001), and anti-thyroglobulin (Anti-TG) (p-value 0.05). Conclusion: While our study did not find a significant association between these two conditions, other studies have reported varying results. Hormonal alterations, autoimmune factors, and genetic predispositions are among the potential mechanisms that could explain the associations observed in some studies.

  • Open Access

    Evaluation of the effects of raloxifene treatment on uterus in asymptomatic postmenoposal patients by transvaginal Doppler ultrasonography

    by Asena Ayar Madenli

    Aims: To evaluate the effects of raloxifene treatment on uterus in asymptomatic postmenopausal patients by Doppler transvaginal ultrasonography (TvUS). Methods: Randomized controlled prospective study, 57 healthy postmenopausal asymptomatic patients, aged 45-60, who applied Okmeydanı Training and Research Hospital Obstetrics and Gynecology Outpatient Clinic between 2003-2004. Four patients were excluded from the study because they did not apply the treatment regularly. All of the patients were in natural menopause. They had not received any hormone replacement therapy before. Their body mass index (BMI) was below 30 kg/m2 and had no systemic diseases. The patients were divided into two groups as those who received raloxifene (n: 27) and those who did not (n: 26). Raloxifene was given 60 mg/day for 6 months. In all patients enrolled in the study, endometrial and uterine volume, pulsatility (PI) and resistance indices (RI) were evaluated by TvUS Doppler. Endometrial biopsies (EB) were obtained with pipelle at 0 and 6 months. Results: There was no significant difference in terms of age, height, weight and BMI (p<0.05). Parity, menopause time and endometrial thickness were similar (p<0.05). EB results were similar (p<0.05). Uterine volumes at month 0 and 6 were similar (p<0.05). PI and RI were found to be similar in the right and left arteries at baseline (p<0.05). While PI and RI on the right side were similar at 6 months, left uterine artery PI was found to be significantly higher in the treated group. Left uterine artery RI was similar. Conclusion: Raloxifene treatment neither did stimulate the endometrium, nor increased the uterine volume or uterine blood flow. It did not have any stimulating effect on the uterine tissue.

  • Open Access

    The pregnancy results were not affected from the administration day of Depot GnRH agonists in artificial cycle frozen-thawed embryo transfers

    by Mehmet Ağar, Asena Ayar Madenli̇, Nur Dokuzeylül Güngör, Şebnem Alanya Tosun

    Aim: In frozen-thawed embryo transfers (FET), Gonadotropin-Releasing Hormone (GnRH) agonists have recently been used to improve implantation results. It is preferred to administer it in the luteal phase of the previous cycle. The objective was to compare the effects of different administration days of depot GnRH agonists on implantation and pregnancy rates in the artificial cycle of FET. Material and Method: A retrospective case-control study was conducted in an in vitro fertilization (IVF) center in a university hospital, including all women starting an artificial cycle of FET. One thousand two hundred and twenty-seven (n:1227) FET cycles were scanned from the files from October 2014 to December 2021. Depot agonists (Lucrin depot 3.75 mg sc Abbott USA.-leuprolide acetate) were used in 219 patients with endometriosis. In 58 patients, it was administered on day 21 of the previous cycle (Group 1), and in 161 patients, it was administered on day 2 of the same cycle (Group 2). Results: This study showed no statistically significant difference between the two groups in laboratory parameters and endometrial thickness (p>0.05). There was no statistically significant association between the abort rate and transfer day (p>0.05). There was no statistically significant association between the pregnancy results and transfer day (p>0.05). The ongoing pregnancy rate (OPR) rate was relatively high in the second group compared to the twenty-first day of the previous cycle (87/161(54%) vs. 30/58 (51.7%)). The biochemical pregnancy was relatively high in the second-day group compared to the twenty-first day of the previous cycle (62/161(38.5%) vs. 21/58 (36.2%)). The abort rate was relatively high in the twenty-first-day group compared to the second day of the cycle (25/87(28.75%) vs. 9/30(30%)). Conclusion: In conclusion, the impacts of various administration days of depot Gonadotropin-releasing hormone (GnRH) agonists on implantation and pregnancy rates were not statistically significant.